Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
24/6/2021
0:00
13:01
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
Altri episodi di "JAMA Oncology Author Interviews"
Non perdere nemmeno un episodio di “JAMA Oncology Author Interviews”. Iscriviti all'app gratuita GetPodcast.